Thought leaders are Optimistic that Emerging Therapies for Previously Treated EGFR-Mutation-Positive NSCLC will Offer Competitive Advantages over Currently Available Treatments

April 29, 2014

Improvements in Key Efficacy Endpoints, Especially Overall Survival, are Pivotal Drivers for Prescribing, According to a New Report from Decision Resources Group

BURLINGTON, Mass., April 29, 2014 /PRNewswire/ — Decision Resources Group finds that interviewed oncologists’ are optimistic that Boehringer Ingelheim’s second-generation irreversible EGFR tyrosine kinase inhibitor (TKI) Gilotrif/Giotrif will offer efficacy and delivery advantages over currently available agents for the second- and subsequent-line treatment of EGFR-mutation-positive non-small cell lung cancer (NSCLC). Interviewed oncologists’ are also optimistic that the third-generation EGFR TKIs CO-1686 (Clovis oncology/Celgene) and AP-26113 (Ariad pharmaceuticals) will offer competitive advantages in efficacy, safety and tolerability and delivery attributes.


Other key findings from the DecisionBase report entitled NSCLC (EGFR-Mutation-Positive; Previously Treated): Are Emerging Targeted Therapies Poised to Fill the Significant Unmet Need of Patients in the Second and Subsequent Lines of Therapy?:

    --  The effect of an emerging therapy on key efficacy endpoints, including
        progression-free survival and median overall survival (MOS), has the
        most influence over surveyed U.S. and European oncologists' prescribing
        decisions for previously treated, EGFR-mutation-positive NSCLC.
    --  The majority of surveyed managed care organization (MCO) pharmacy
        directors are receptive of emerging therapies that offer improvements in
        MOS for the treatment of this patient population.
    --  Based on key thought leader's opinions, Gilotrif/Giotrif, CO-1686 and
        AP-26113 could all offer a level of MOS that, according to surveyed U.S.
        MCO pharmacy directors, would be necessary for inclusion on MCO
    --  Interviewed experts are enthusiastic about the third-generation EGFR
        TKIs CO-1686 and AP-26113 and consider them to have the strongest
        clinical profiles among the current and emerging therapies for
        previously treated, EGFR-mutation-positive NSCLC.

Comments from Decision Resources Group Analyst Jennifer Bamford:

    --  "Current second- and subsequent-line treatment of EGFR-mutation-positive
        NSCLC consists of chemotherapy regimens, which typically result in low
        tumor response rates and short progression-free intervals. Based on
        interviewed physicians and available clinical data the second- and
        third-generation EGFR TKI inhibitors are set to fulfill this unmet
    --  "The anticipated future approval of the second- and third-generation
        EGFR TKIs for EGFR-mutation-positive patients will further advance the
        personalized treatment approach in NSCLC."

About Decision Resources Group

Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group

Christopher Comfort



Logo – http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group

Source: PR Newswire

comments powered by Disqus